Cannabis Blog

Nearly one in four American adults used cannabis in the past year, according to a new study in Addictive Behaviors. We break down how they consume it, why tobacco users lead the pack, and how the US stacks up against Canada and Europe's biggest markets.

Legalization skeptics warned that regulated markets would hook a generation of teens. Federal data says otherwise: high-school cannabis use is at its lowest point in three decades, and Germany's first post-legalization survey points the same way. We break down the figures.

Only two molecules drive almost every UK cannabis prescription, yet the plant holds more than 100 cannabinoids. We look at why its pharmaceutical potential is still largely untapped, how dosing tolerances stack up, and what better delivery could unlock for patients.

Nine pharmacies, three Swiss cities and 1,177 cannabis users: the SCRIPT trial's interim data shows legal access nudging consumers toward vapes, exposing contaminated street product and raising almost no police concerns. Here's what the numbers mean for growers and regulators.

Europe’s cannabis market is changing, but its health impact remains uncertain. Stronger resin, new products and diverging national laws complicate the picture. Here’s what the latest EUDA evidence reveals—and what the figures cannot tell us about use and harm.

From Germany's Cannabis Act to Spain's hospital pharmacies, Europe is rewriting the rules on cannabis medicine. We unpack the 17.6% CAGR behind a fourfold rise in market value, the segments pulling ahead, from indica flower to CBD oils, and the barriers still slowing patient access.

Germany's prices are tumbling, the UK's patient count is climbing and Portugal is shipping tonnes across the continent. We break down the figures behind Europe's fastest-moving cannabis markets, from Swiss pilot trials to the 2029 forecasts, and what it all means for growers.

Germany's April 2024 reform legalised possession and home growing but never built a legal market. We look at what two years of real-world data reveal: why home cultivation thrived, why the social clubs stalled, how medical prescriptions exploded, and what growers elsewhere should take from it.

More than 1,000 medicinal cannabis products sit on pharmacy shelves, but only two have ever passed full regulatory assessment. We look at how special access pathways became the norm, what that gap means for patients and prescribers, and why honest genetics matter more than ever.